DEF: SANUWAVE Health Faces Governance Scrutiny and Financial Challenges Amidst Auditor Changes and Equity Plan Expansion

SANUWAVE Health, Inc. is seeking shareholder approval for director elections, auditor ratification, and a significant increase in its equity incentive plan, while grappling with persistent financial losses, material weaknesses in internal controls, and a history of delinquent insider trading reports.

Summary

• SANUWAVE Health, Inc. will hold its annual stockholder meeting virtually on August 19, 2025, to vote on five key proposals.
• Shareholders will vote on the election of five directors: Morgan Frank, Gregory Bazar, Jeffrey Blizard, Ian Miller, and James Tyler, to serve until the 2026 annual meeting.
• The company is seeking ratification of Baker Tilly US, LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025.
• A significant proposal includes amending the 2024 Equity Incentive Plan to increase the number of shares authorized for issuance by 500,000, bringing the total to 1,876,556 shares, citing insufficient shares for future compensation needs through 2025.
• The current overhang (outstanding equity awards plus shares available for future grants) is approximately 13.5% of fully diluted shares, which would increase to 17.5% if the additional 500,000 shares are approved.
• Shareholders will also cast advisory, non-binding votes on named executive officer compensation and the frequency of future such votes (Board recommends annually).
• The company effected a 1-for-375 reverse stock split on October 18, 2024, adjusting all historical share and per share amounts.
• As of the Record Date (July 8, 2025), there were 8,569,338 shares of common stock outstanding and entitled to vote.
• The market value of one share of common stock on the Record Date was $34.89.
• The company reported net losses of $(31,372) thousand in 2024, $(25,807) thousand in 2023, and $(10,293) thousand in 2022.
• Total shareholder return based on a $100 investment from December 31, 2021, declined to $36.08 by 2024, from $7.65 in 2023 and $13.41 in 2022.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to persistent and significant net losses, the auditor's 'going concern' warning, identified material weaknesses in internal controls, and a pattern of delinquent insider trading reports. While there are efforts to improve governance and compensation alignment, the fundamental financial and compliance issues are severe.

Positives

• The Board has established a Strategy and Finance Committee focused on identifying financial strategies to improve the balance sheet and stockholder value.
• The company's executive compensation program is designed to align executive pay with performance and link it to measurable results, aiming to create stockholder value and attract/retain talent.
• The Board has designated an independent Lead Director (Ian Miller) given that the Chairman and CEO roles are combined and held by a non-independent director.

Negatives

• The company has experienced significant net losses for three consecutive fiscal years: $(31,372) thousand in 2024, $(25,807) thousand in 2023, and $(10,293) thousand in 2022.
• The independent registered public accounting firm, Marcum LLP, included a paragraph in its reports for 2024 and 2023 regarding substantial doubt about the company's ability to continue as a going concern.
• Material weaknesses in internal control over financial reporting were identified, including a lack of internal controls over key accounting and IT processes, and insufficient expertise/resources to properly apply U.S. GAAP to complex transactions and financial instruments.
• There were numerous instances of delinquent Section 16(a) reports for directors, executive officers, and significant beneficial owners, indicating compliance issues.
• The company underwent two changes in its independent registered public accounting firm within a short period in 2025 (Marcum to CBIZ CPAs, then CBIZ CPAs to Baker Tilly US, LLP).
• Total shareholder return has significantly declined, with a $100 investment from December 31, 2021, dropping to $36.08 by 2024.

Risks

• Substantial doubt about the company's ability to continue as a going concern, as noted by the former independent auditor.
• Material weaknesses in internal control over financial reporting, which could lead to inaccuracies in financial statements and non-compliance with regulatory requirements.
• Potential for further dilution of existing stockholders if the proposed increase in shares for the 2024 Equity Incentive Plan is approved, increasing overhang from 13.5% to 17.5%.
• Challenges in attracting and retaining talent if the equity incentive plan is not approved, potentially leading to increased cash compensation expenses and depletion of cash reserves.
• Compliance risks related to the numerous delinquent Section 16(a) reports by directors, executive officers, and major shareholders.

Future Outlook

The company anticipates that the additional 500,000 shares reserved under the 2024 Equity Incentive Plan, if approved, will be sufficient to enable equity awards for approximately the next one or two years. The Board recommends holding future advisory votes on named executive officer compensation annually to promote communication with stockholders and provide direct input.

Management Comments

• The Board believes that Mr. Frank's extensive experience in life sciences investing, corporate restructuring, and public company leadership qualify him to serve on the Board.
• The Board believes that Mr. Blizard's deep experience in medical device sales leadership, market development, and commercialization of capital equipment qualify him to serve on the Board.
• The Board believes that Mr. Miller's extensive experience in global sales leadership and strategic business development qualify him to serve on the Board.
• The Board believes that Mr. Tyler's extensive operational and financial leadership in healthcare, particularly his experience in the wound care industry, qualify him to serve on the Board.
• The Board believes that Mr. Bazar's leadership in engineering, technology innovation, and cybersecurity, along with his experience guiding companies through growth and acquisition, qualify him to serve on the Board.
• The Board believes that combining the roles of chairman and chief executive officer is currently in the best interest of the Company and its stockholders, promoting open communication and efficient decision-making with independent oversight.
• The Board believes the amendment to the 2024 Plan is in the best interests of the Company and our stockholders because it aligns executive, employee, and stockholder interests, helps attract and retain talent, avoids disruption in compensation programs, and mitigates the need for significant cash compensation.

Industry Context

The document primarily focuses on internal corporate governance, executive compensation, and financial reporting compliance, rather than broader industry trends or competitive positioning. The company operates in the life sciences and medical device sectors, as indicated by the experience of its directors and the nature of its products (e.g., wound care, insulin delivery, medical device technology). The emphasis on equity compensation reflects a common practice in competitive talent markets within the life sciences and technology industries.

Comparison to Industry Standards

• The company's reported material weaknesses in internal control over financial reporting and the 'going concern' doubt expressed by its former auditor are significant deviations from expected industry standards for publicly traded companies, which are expected to maintain robust financial controls and demonstrate financial viability.
• The high number of delinquent Section 16(a) reports for insiders suggests a lapse in compliance practices compared to typical public company standards.
• The frequent changes in independent registered public accounting firms (Marcum to CBIZ CPAs, then CBIZ CPAs to Baker Tilly US, LLP within months) are unusual and may signal underlying issues that are not standard practice in the industry.
• The proposed increase in the equity incentive plan shares and the resulting overhang of 17.5% should be evaluated against peer companies in the life sciences and medical device sectors to determine if it represents a reasonable level of dilution for talent attraction and retention.

Management Changes

Corporate Governance

Related Party Transactions

• In August and November 2022, the company sold $16.2 million and $4.0 million, respectively, in Future Advance Convertible Promissory Notes and Common Stock Purchase Warrants to related parties including James Besser, Morgan C. Frank (Chairman & CEO), Kevin A. Richardson, II (former Chairman & CEO), A. Michael Stolarski (former director), Manchester Explorer, L.P., and Opaleye, L.P. Some notes were for accrued/unpaid director fees.
• In May and December 2023, Manchester Explorer, L.P. purchased an aggregate principal amount of $300,000 and $100,000, respectively, in Notes and Warrants.
• In July 2023, the company issued $4.6 million in Asset-Backed Secured Promissory Notes to A. Michael Stolarski, Manchester Explorer, L.P., and Opaleye, L.P., which converted to convertible notes in January 2024.
• In June 2024, the company issued a $0.5 million promissory note to Manchester Explorer, L.P., bearing 15% interest, which was paid in full in October 2024.
• In October 2024, Manchester Explorer, L.P. purchased $1.5 million of common stock in a private placement that raised approximately $10.3 million gross proceeds.
• In October 2024, the company exchanged all outstanding Notes and Warrants from various private placements (August 2022, November 2022, May 2023, December 2023, January 2024, and June 2024) for 3,989,456 shares of common stock, with Notes converting at $15.00 per share.

Stakeholder Impact

• **Shareholders**: Face potential dilution from the proposed increase in the equity incentive plan. Have the opportunity to vote on key governance matters, including director elections and executive compensation. Are directly impacted by the company's ongoing net losses and the 'going concern' warning.
• **Employees**: Benefit from the 2024 Equity Incentive Plan, which is intended to attract and retain talent through stock-based compensation. The termination of the Chief Commercial Officer indicates potential for management changes.
• **Customers**: Not directly addressed in this governance-focused filing, but the company's financial health and strategic direction could indirectly affect product development and service quality.
• **Suppliers/Creditors**: The 'going concern' warning and history of related-party debt/equity conversions could raise concerns about the company's ability to meet future obligations, potentially impacting terms with suppliers and creditors.
• **Management**: Subject to compensation decisions and performance goals, with a significant portion of executive compensation tied to equity awards. The CEO and President received substantial option awards in 2024. Management is responsible for addressing the identified material weaknesses in internal controls and compliance issues.

Next Steps

• Hold the annual stockholder meeting virtually on August 19, 2025, for voting on proposals.
• Publish final voting results in a Current Report on Form 8-K within four business days of the Stockholder Meeting.
• The Audit Committee will reconsider retaining Baker Tilly US, LLP if stockholders fail to ratify their appointment.
• The Compensation Committee will consider the outcome of the advisory vote on executive compensation when making future compensation decisions.
• The Board will consider the frequency option receiving the most votes for future advisory votes on executive compensation.
• Stockholders wishing to present proposals for the 2026 Annual Meeting must submit them by April 1, 2026 (for inclusion in proxy statement) or between February 11, 2026, and March 13, 2026 (for other proposals/nominations).

Key Dates

Recommendation

Keywords

Proxy Statement, Corporate Governance, SEC Filing, Shareholder Meeting, Director Election, Auditor Ratification, Equity Incentive Plan, Executive Compensation, Internal Controls, Going Concern, Related Party Transactions, Reverse Stock Split, Stock Options, Nasdaq, Risk Management